

Erratum

Erratum: Management of aneurysmal subarachnoid hemorrhage: State of the art and future perspectives

In the article titled, “Management of aneurysmal subarachnoid hemorrhage: State of the art and future perspectives” published as eLocation ID 11, in vol. 8 of Surgical Neurology International,^[1] the last sentence under the heading “Endothelin receptor antagonists” is written incorrectly as “Furthermore, the occurrence of adverse events in the clazosentan group (i.e., pulmonary edema, hypotension, cerebrovascular spasm, pleural effusion, and cerebral infarction) halted the study and prevented the CONSCIOUS-3 to be further continued.^[61]” instead the correct sentence is “In particular, pulmonary complications, anemia, and hypotension were more common in patients treated with clazosentan.^[61] The CONSCIOUS-3 study, which was running in parallel to CONSCIOUS-2, was prematurely terminated due to the inconclusive results from CONSCIOUS-2.”

REFERENCE

1. Grasso G, Alafaci C, Macdonald RL. Management of aneurysmal subarachnoid hemorrhage: State of the art and future perspectives. *Surg Neurol Int* 2017;8:11.

DOI: 10.4103/2152-7806.205273